EP
MRVI icon

Eversept Partners’s Maravai LifeSciences MRVI Stock Holding History

Eversept Partners’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-718,582
Closed -$2.34M – 140
2025
Q4 		$2.34M Buy
718,582
+427,909
+147% +$1.44M 0.12% 83
2025
Q3 		$834K Sell
290,673
-350,000
-55% -$894K 0.06% 79
2025
Q2 		$1.54M Sell
640,673
-301,781
-32% -$634K 0.14% 56
2025
Q1 		$2.08M Buy
+942,454
New +$3.72M 0.21% 44
2024
Q4 		– Sell
-336,966
Closed -$2.8M – 76
2024
Q3 		$2.8M Buy
+336,966
New +$2.91M 0.19% 54
2023
Q4 		– Sell
-452,323
Closed -$4.52M – 66
2023
Q3 		$4.52M Buy
+452,323
New +$4.97M 0.38% 46
2022
Q4 		– Sell
-160,000
Closed -$4.08M – 78
2022
Q3 		$4.08M Sell
160,000
-265,364
-62% -$6.66M 0.35% 39
2022
Q2 		$12.1M Buy
+425,364
New +$13.5M 0.86% 33
2022
Q1 		– Sell
-87,795
Closed -$3.68M – 100
2021
Q4 		$3.68M Sell
87,795
-240,015
-73% -$9.72M 0.24% 68
2021
Q3 		$16.1M Buy
327,810
+252,810
+337% +$12.3M 1.11% 25
2021
Q2 		$3.13M Buy
+75,000
New +$2.91M 0.21% 58

Other funds holding MRVI

GL
GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
1WCM
12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Eversept Partners's MRVI Position: Q1 2026 in Review

Eversept Partners sold out of Maravai LifeSciences (MRVI) in Q1 2026, closing a stake of 718,582 shares — an estimated $2.34M sold.

Eversept Partners first reported a position in MRVI in Q2 2021 and held it in 11 quarters. The position peaked at $16.1M in Q3 2021. 158 funds tracked by Wall St. Rank hold MRVI as of Q1 2026.

  • Eversept Partners reported no remaining Maravai LifeSciences position as of Q1 2026 after selling out during the quarter.
  • Eversept Partners sold 718,582 Maravai LifeSciences shares in Q1 2026, an estimated $2.34M.
  • Eversept Partners first reported a position in Maravai LifeSciences in Q2 2021 and held it in 11 quarters.
  • Eversept Partners's Maravai LifeSciences position peaked at $16.1M in Q3 2021.
  • 158 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q1 2026.

Based on Eversept Partners's 13F filing for Q1 2026, filed 15 May 2026.